About Fabry Disease
Fabry disease is an inheritable lysosomal storage disease characterized by the excessive accumulation of globotriaosylceramide (GL-3) in lysosomes. It results from a deficiency of a-Gal and can result in symptoms such as fatigue, angiokeratoma, tinnitus, kidney failure, heart disorders, and nervous system problems. Fabry disease results from mutations in the galactosidase (GLA) gene, resulting in decreased activity or complete absence of a-Gal. Fabry disease resulting from the decreased activity of the enzyme is called later-onset Fabry disease. This form of the disease can effect both males and females. The symptoms of this disease typically appear during adulthood and usually focus on a single organ. Fabry disease resulting from the complete absence of a-Gal results in a more severe form called classic Fabry disease. The classic form of the disease usually affects males. The disease symptoms usually starts in adolescence and include clouded eye lenses, skin lesions, pain, and reduced sweating. If untreated, the disease can lead to cardiac dysfunction, renal failure or stroke, often resulting in death during fourth or fifth decade of life.
TechNavio's analysts forecast the Global Fabry Disease market to grow at a CAGR of 18.08 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Fabry Disease market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various innovator drugs available in the market for the treatment of fabry disease.
TechNavio's report, the Global Fabry Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Fabry Disease market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Genzyme
• Shire
Other Prominent Vendors
• Amicus Therapeutics
• Green Cross Corporation
• ISU Abxis
• JCR Pharmaceuticals
• Protalix Biotherapeutics
Market Driver
• Special Provisions for Orphan Drugs
• For a full, detailed list, view our report
Market Challenge
• Limited Patient Population
• For a full, detailed list, view our report
Market Trend
• Regulatory Assistance in Emerging Countries
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Disease Overview
05.1 Lysosomal Storage Disorders
05.2 Fabry Disease
05.2.1 Etiology and Pathophysiology
05.2.2 Signs and Symptoms
05.2.3 Epidemiology
05.2.4 Inheritance Pattern
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Historical Analysis of Global Fabry Disease market
07.4 Five Forces Analysis
08. Market Segmentation by Cell Line Used for Manufacturing the Drug
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2014
17.3 Other Prominent Vendors and Future Vendors
18. Pipeline Analysis
18.1 Clinical Trial Analysis of Pipeline Candidates
18.1.1 AT1001
18.1.2 GZ402671
18.1.3 PRX-102
19. Fabry Registry
20. Key Vendor Analysis
20.1 Genzyme
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Product Segmentation by Revenue 2013
20.1.4 Product Segmentation by Revenue 2012 and 2013
20.1.5 Geographical Segmentation
20.1.6 Business Strategy
20.1.7 Recent Developments
20.1.8 SWOT Analysis
20.2 Shire
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Geographical Segmentation by Revenue 2013
20.2.4 Business Strategy
20.2.5 Recent Developments
20.2.6 SWOT Analysis
21. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Classification of Lysosomal Storage Diseases
Exhibit 3: Difference between Normal Cell and Fabry Disease Cell
Exhibit 4: Fabry Disease Symptoms by Age
Exhibit 5: Enzymatic Activity of ?-GAL
Exhibit 6: Global Lysosomal Storage Diseases Market 2014-2019 (US$ billion)
Exhibit 7: Percentage Share of Fabry Disease in Global Lysosomal Storage Diseases Market 2014
Exhibit 8: Percentage Share of Fabry Disease in Global Lysosomal Storage Diseases Market 2014 and 2019
Exhibit 9: Global Fabry Disease Market 2014-2019 (US$ million)
Exhibit 10: Global Fabry Disease Market 2004-2014 (US$ million)
Exhibit 11: Global Fabry Disease Market Segmentation by Cell Line Used for Manufacturing the Drug
Exhibit 12: Market Share of Global Fabry Disease Market Segments 2014
Exhibit 13: Global Fabry Disease Market Segmentation by Drugs 2004-2014 (US$ million)
Exhibit 14: Sales of Fabry Disease Drugs 2004-2014 (US$ million)
Exhibit 15: Global Fabry Disease Market Segmentation by Drugs 2004-2014
Exhibit 17: Global Fabry Disease Market Segmentation by Geography 2014
Exhibit 18: Global Fabry Disease Market Share Analysis 2014
Exhibit 19: Key Event Timeline for Fabrazyme
Exhibit 20: Revenue of Fabrazyme 2004 - 2014(H1) (US$ million)
Exhibit 21: Impact of Lowered Dose of Fabrazyme by Country
Exhibit 22: Key Event Timeline for Replagal
Exhibit 23: Revenue of Replagal 2004 - 2014(H1) (US$ million)
Exhibit 24: Key Active Patents for Replagal
Exhibit 25: Clinical Trial Locations for AT1001
Exhibit 26: List of Clinical Trial Locations for AT1001
Exhibit 27: AT1001 Phase III Trial Locations
Exhibit 28: List of AT1001 Phase III Trial Locations
Exhibit 29: GZ402671 Phase II Trial Locations
Exhibit 30: List of GZ402671 Phase II Trial Locations
Exhibit 31: PRX-102 Phase 1/II Trial Locations
Exhibit 32: List of PRX-102 Phase 1/II Trial Locations
Exhibit 33: Enrolment Statistics for Fabry Registry
Exhibit 34: Enrolment Statistics for Fabry Registry by Geography 2012
Exhibit 35: Genzyme: Product Segmentation by Revenue 2013
Exhibit 36: Genzyme: Product Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 37: Genzyme: Geographical Segmentation
Exhibit 38: Shire: Geographical Segmentation by Revenue 2013
